Investment analysts at Oppenheimer assumed coverage on shares of OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $35.00 price target on the stock. Oppenheimer’s price objective indicates a potential upside of 90.01% from the stock’s previous close. […]

Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $47.00 price objective on the stock. Bicara Therapeutics Stock Performance Shares of BCAX stock opened at $19.41 on Tuesday. Bicara Therapeutics has a […]

Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Bicara Therapeutics’ FY2024 earnings at ($1.61) EPS. Several other research analysts also recently commented on […]

Stock analysts at Rodman & Renshaw started coverage on shares of Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set a “buy” rating and a $50.00 price target on the stock. Separately, HC Wainwright boosted their price target on Monopar Therapeutics […]

UBS Group assumed coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX – Free Report) in a research note published on Thursday, MarketBeat reports. The firm issued a buy rating and a $13.00 target price on the stock. KYTX has been the topic of several other reports. Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a […]